Across TCGA pan-cancer cohorts, MIR155HG Mutation is linked to patient survival in 1 of 34 cancer types, making it a survival-associated MIR155HG data layer compared with 24 for mass-spec protein.
The strongest signal is observed in stomach adenocarcinoma (STAD), where higher MIR155HG Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated MIR155HG expression acts as an unfavorable survival marker.
STAD are the cancer types where MIR155HG Mutation most reproducibly stratifies survival.